Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability ...

A team of researchers has developed a new gene therapy for children with Dravet syndrome, a rare type of epilepsy in children ...

One such condition is Dravet syndrome (DS), which typically emerges ... and cardiac arrhythmias. These symptoms lead to premature death within the first three weeks of life. The study aimed ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the comp ...

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Similarly, most current investigational candidates only target the symptoms. One exception is ... More than 85% of people with Dravet syndrome have an SCN1A mutation. Stoke is aiming to help ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United ...

(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics, Inc. (STOK) Tuesday announced partnership to develop and sell zorevunersen, Stoke's drug candidate for the treatment of Dravet syndrome ...